Genmab Stock-Based Compensation 2010-2025 | GNMSF

Genmab stock-based compensation for the twelve months ending March 31, 2025 was $0.259B, a 137.21% increase year-over-year.

  • Genmab annual stock-based compensation for 2024 was $0.105B, a 22.87% increase from 2023.
  • Genmab annual stock-based compensation for 2023 was $0.085B, a 36.88% increase from 2022.
  • Genmab annual stock-based compensation for 2022 was $0.062B, a 26.04% increase from 2021.

Genmab Stock-Based Compensation 2010-2025 | GNMSF

  • Genmab annual stock-based compensation for 2024 was $0.105B, a 22.87% increase from 2023.
  • Genmab annual stock-based compensation for 2023 was $0.085B, a 36.88% increase from 2022.
  • Genmab annual stock-based compensation for 2022 was $0.062B, a 26.04% increase from 2021.